Last reviewed · How we verify

PIBD-Net — Portfolio Competitive Intelligence Brief

PIBD-Net pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Azathioprine / 6 Mercaptopurine Azathioprine / 6 Mercaptopurine marketed Purine analog immunosuppressant Hypoxanthine-guanine phosphoribosyltransferase (HGPRT), inosine monophosphate dehydrogenase (IMPDH) Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. University Hospital Schleswig-Holstein · 1 shared drug class
  2. Védrines, Philippe, M.D. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for PIBD-Net:

Cite this brief

Drug Landscape (2026). PIBD-Net — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pibd-net. Accessed 2026-05-15.

Related